Fundamental Analysis of BiondVax Pharmaceuticals Ltd. - Growth / Value Index
BVXV - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Price to Book Ratio of 1099.29 suggesting that it is very expensive
Book value is negative
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 140.98 | -175.32 | -47845.78 % | |
Price to Book | 1099.29 | -577.35 | -92254.30 % | -0.646 |
Price to Sales | 348.44 | 0 | 0 % | |
Enterprise Value to EBITDA Multiple | -1.01 | -97.39 | -10479.80 % |
BVXV - Profitability Highlights
Profitability Analysis
During the past twelve months, the company has given a strong Return On Equity of 779.74%
During the past twelve months, the company has given a strong Net Margin of 247.15%
Tsr Profitability Index - Very Poor Score of 17.50
Piotroski F Score - Very Poor Value of 1.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
EPS decline for last four quarters
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 779.74 | 0 | 0 % | 0 |
Return On Asset | 10.63 | -21.41 | 46.65 % | -18.91 |
Net Profit Margin | 247.15 | 0 | 0 % | 0 |
Operating Profit Margin | -611.15 | 0 | 0 % | 0 |
EBITDA Margin | -557.04 | 0 | 0 % | 0 |
Highlights
Market Cap | 4966.62 K |
Enterprise Value | 11355.62 K |
Price/Book TTM | 1099.29 |
Outstanding Share | 3651.93 K |
Float/ Outstanding Share | 74.49% |
Dividend Yield | 0 % |
Share Holding
Guru Numbers
Price/Graham No | |
Peter Lynch Ratio | 0 |
Piotroski F Score | 1.00 |
Altman Z Score | -6.70 |
Sloan Ratio | 0.054 |
Peter Lynch Fair Value | 0.203 |
BVXV - Growth Highlights
Growth Analysis
Tsr Growth Index - Very Poor Score of 14.42
Quarterly sales in last 5 Quarter is trending down
Annual sales in last 3 years is trending down
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 2016.00 K | 100.00 % | 100.00 % |
Gross Profit | 2016.00 K | 100.00 % | 100.00 % |
EBITDA | -11230.00 K | 60.72 % | 72.02 % |
Net Profit | 4982.56 K | 85.50 % | 167.21 % |
EPS | 0.0096 | 99.79 % | NA |
BVXV - Stability Highlights
Stability Analysis
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
Cash ratio of 6.02
Tsr Stability Index - Poor Score of 20.31
Altman Z Score of -6.70 suggest high risk
Company is unable to generate enough free cash to support the business.
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | -11.63 | -523.74 % | -3.33 |
Cash Ratio | 6.02 | -19.71 % | |
Quick Ratio | 0 | 0 % | 4.12 |
Shareholders Equity | -6.50 | -127.76 % | |
Debt to EBITDA | -1.95 | 18.62 % |
Historical Valuation Ratios of BiondVax Pharmaceuticals Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of BiondVax Pharmaceuticals Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of BiondVax Pharmaceuticals Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of BiondVax Pharmaceuticals Ltd.
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)